Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo

Trial Profile

Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Vitiligo
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 24 Apr 2017 Results from this trial will be presented at the 76th Annual Society for Investigative Dermatology Meeting, according to an Aclaris Therapeutics media release.
    • 05 Apr 2017 Primary endpoint of percent change in Vitiligo Area Severity Index (VASI) score has been met, according to results published in the Journal of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top